Prediction: Lilly Will Trade at Record High in 12 Months
Eli Lilly stock is surging on fresh obesity-drug data, fueling bets that the name could push toward a record high wit...
Eli Lilly
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
39 articles
Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Prediction: Lilly Will Reach $1,200 in 2026 — Investment Thesis
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Health Just Announced Fantastic News for Lilly Investors
A major payer shift could unlock stronger demand for Eli Lilly’s obesity and GLP-1 products. This in-depth analysis e...
Reasons Lilly Remains a Buy: 3 Strong Drivers for Investors
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
These Words From Lilly's CEO Signal Bullish Wall Street
A single conference-call moment changed the mood around Eli Lilly. By unpacking eight key themes from the CEO, invest...
Stock Split Watch: Lilly — Is Eli Lilly Next to Split?
Eli Lilly has been a standout growth stock thanks to GLP-1 drug demand. Could a stock split be on the horizon? This g...
Novo Nordisk Beating Lilly in Obesity Pill Market: What It Means for Investors
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...
Lilly Just Made Game-Changing Moves in Weight-Loss Space
A big strategic shift from Lilly could redefine how investors view weight-loss drugs. This article breaks down what h...
Can Lilly Stock Reach $1800 by 2030? Bulls See Path
Eli Lilly kicked off 2026 with blockbuster sales and higher guidance, reigniting talk of a path to $1800 for Lilly st...
Should Lilly Investors Worry About Its Rival From Within
Eli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...